Amalgamated Bank Alaunos Therapeutics, Inc. Transaction History

Amalgamated Bank

$12.2 Billion
Q4 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $14,036 - $42,452	-34,236 Closed	0 $0
Q1 2022 Jun 30, 2022	SELL	$0.62 - $1.17 $1,718 - $3,242	-2,771 Reduced 7.49%	34,236 $22,000
Q4 2021 Feb 15, 2022	SELL	$1.09 - $1.89 $1,112 - $1,929	-1,021 Reduced 2.68%	37,007 $40,000
Q3 2021 Oct 29, 2021	SELL	$1.44 - $2.73 $2,242 - $4,250	-1,557 Reduced 3.93%	38,028 $69,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $30,116 - $42,025	11,451 Added 40.7%	39,585 $105,000
Q4 2020 Feb 12, 2021	BUY	$2.09 - $3.09 $296 - $438	142 Added 0.51%	28,134 $70,000
Q3 2020 Oct 30, 2020	SELL	$2.39 - $3.43 $1,448 - $2,078	-606 Reduced 2.12%	27,992 $71,000
Q2 2020 Aug 10, 2020	BUY	$2.2 - $3.71 $154 - $259	70 Added 0.25%	28,598 $94,000
Q1 2020 May 13, 2020	BUY	$1.9 - $4.98 $209 - $547	110 Added 0.39%	28,528 $70,000
Q3 2019 Nov 13, 2019	SELL	$4.13 - $6.94 $1,024 - $1,721	-248 Reduced 0.87%	28,418 $122,000
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $32,027 - $49,891	8,047 Added 39.03%	28,666 $167,000
Q1 2019 May 15, 2019	BUY	$2.0 - $4.4 $1,380 - $3,036	690 Added 3.46%	20,619 $79,000
Q4 2018 Feb 15, 2019	BUY	$1.61 - $3.62 $32,085 - $72,142	19,929 New	19,929 $37,000
Q3 2018 Nov 14, 2018	SELL	$2.26 - $3.27 $45,247 - $65,468	-20,021 Closed	0 $0
Q2 2018 Jul 18, 2018	BUY	$3.02 - $4.94 $7,000 - $11,450	2,318 Added 13.09%	20,021 $60,000
Q1 2018 May 22, 2018	SELL	$3.46 - $5.14 $1,006 - $1,495	-291 Reduced 1.62%	17,703 $69,000
Q4 2017 Feb 13, 2018	BUY	$4.0 - $6.54 $5,388 - $8,809	1,347 Added 8.09%	17,994 $74,000
Q3 2017 Nov 09, 2017	BUY	$4.99 - $6.57 $83,068 - $109,370	16,647	16,647 $102,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $352M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account